High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70270 ↗At a glance
Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Misi Gu and 13 co-authors. Institution: Department of Infectious Diseases, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease,…. Major MEDLINE topics: Hepatitis B Surface Antigens, Antiviral Agents, Hepatitis B, Chronic, Hepatitis B virus. Cited 5 times so far (Crossref); 51 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (original language)
Background
The profiles of hepatitis B virus (HBV) integration related to hepatitis B surface antigen (HBsAg) loss remain largely unknown.
Aims
We aimed to delineate the patterns of HBV integration in virally suppressed chronic hepatitis B (CHB) patients and their association with HBsAg loss following antiviral therapy.
Methods
Forty‐five patients with paired liver biopsies were randomly selected from the Anchor study for high‐throughput viral integration detection. The primary endpoint was HBsAg loss at Week 96. In Group II (pegylated interferon alpha‐2b & entecavir), 13 patients achieved HBsAg loss, whereas all patients in Group I (entecavir monotherapy) and 17 in Group II failed to achieve HBsAg loss.
Results
At baseline, the level of clonal expansion was positively correlated with the duration of nucleos(t)ide analogue (NUC) treatment, the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, whereas no association was observed with the HBsAg, hepatitis B core‐related antigen (HBcrAg), HBV RNA or covalently closed circular DNA (cccDNA) levels. Patients with less than 28 breakpoint types achieved a significantly higher rate of HBsAg loss following Peg‐IFN‐based therapy at Week 48 and 96, compared to those with more than 28.
Conclusions
The duration of NUC treatment, as well as ALT and AST levels, were associated with the level of clonal expansion in virally‐suppressed patients. A lower number of breakpoint types at baseline may be related to a higher HBsAg loss rate following Peg‐IFN‐based treatment and serve as a useful marker in guiding treatment decision‐making (NCT02327416). Trial Registration The Anchor study is registered at ClinicalTrials.gov , NCT02327416
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Infectious Diseases, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Tongji Hospital, Huazhong University of Science and Technology, Wuhan…
ORCID profiles: Tao Chen, Di Wu, Qin Ning, Meifang Han
Funding
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Cite
APA
Gu, M., Wu, W., You, J., Wu, Q., Huang, F., Zhang, Y., Wang, P., Xi, D., Yan, W., Wang, X., Chen, T., Wu, D., Ning, Q., & Han, M. (2025). High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70270
Vancouver
Gu M, Wu W, You J, Wu Q, Huang F, Zhang Y, et al. High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70270
BibTeX
@article{Gu2025,
author = {Gu, Misi and Wu, Wenyu and You, Jie and Wu, Qianjun and Huang, Fei and Zhang, Yixuan and Wang, Peng and Xi, Dong and Yan, Weiming and Wang, Xiaojing and Chen, Tao and Wu, Di and Ning, Qin and Han, Meifang},
title = {High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70270}
}
EUVIMED